Analysts Estimate Report : What to Look Out for Interpace Diagnostics Group Stock Forecast, Price & News (NASDAQ:IDXG)

0
206

Earnings results for Interpace Diagnostics Group Stock Forecast, Price & News (NASDAQ:IDXG)

Estimate Momentum measures change in analyst sentiment over time and may be an indicator of future price movements. The Change in Consensus chart shows the current, 1 week ago, and 1 month ago consensus earnings per share (EPS*) forecasts. For the fiscal quarter endingJun 2020 , the consensus EPS* forecast has remained the same over the past week at -1.64 and remained the same over the past month at -1.64. none raised and none lowered their forecast. For the fiscal year ending Dec 2020 , the consensus EPS* forecast has remained the same over the past week at -5.3 and remained the same over the past month at -5.3 . none raised and none lowered their forecast.

Interpace Diagnostics Group last announced its quarterly earnings data on June 25th, 2020. The business services provider reported ($2.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.24) by $1.08. The business earned $9.20 million during the quarter, compared to analyst estimates of $8.95 million. Interpace Diagnostics Group has generated ($5.58) earnings per share over the last year. Interpace Diagnostics Group has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, August 18th, 2020 based off prior year’s report dates.

Analyst Opinion on Interpace Diagnostics Group Stock Forecast, Price & News (NASDAQ:IDXG)

5 Wall Street analysts have issued ratings and price targets for Interpace Diagnostics Group in the last 12 months. Their average twelve-month price target is $8.81, predicting that the stock has a possible upside of 127.13%. The high price target for IDXG is $12.00 and the low price target for IDXG is $3.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of “Buy.”

Interpace Diagnostics Group has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $8.81, Interpace Diagnostics Group has a forecasted upside of 127.1% from its current price of $3.88. Interpace Diagnostics Group has only been the subject of 1 research reports in the past 90 days.

Dividend Strength: Interpace Diagnostics Group Stock Forecast, Price & News (NASDAQ:IDXG)

Interpace Diagnostics Group does not currently pay a dividend. Interpace Diagnostics Group does not have a long track record of dividend growth.

Insiders buying/selling: Interpace Diagnostics Group Stock Forecast, Price & News (NASDAQ:IDXG)

In the past three months, Interpace Diagnostics Group insiders have not sold or bought any company stock. 54.40% of the stock of Interpace Diagnostics Group is held by insiders. A high percentage of insider ownership can be a sign of company health. Only 18.83% of the stock of Interpace Diagnostics Group is held by institutions.

Earnings and Valuation of Interpace Diagnostics Group Stock Forecast, Price & News (NASDAQ:IDXG

Earnings for Interpace Diagnostics Group are expected to grow in the coming year, from ($5.30) to ($2.00) per share. The P/E ratio of Interpace Diagnostics Group is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Interpace Diagnostics Group is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Interpace Diagnostics Group has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

More latest stories: here